Metagenomi (NASDAQ:MGX – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Institutional & Insider Ownership
89.1% of Kodiak Sciences shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Metagenomi and Kodiak Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Metagenomi | $52.30 million | 1.17 | -$68.25 million | ($2.62) | -0.63 |
| Kodiak Sciences | N/A | N/A | -$260.49 million | ($3.65) | -0.90 |
Analyst Ratings
This is a summary of recent recommendations and price targets for Metagenomi and Kodiak Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Metagenomi | 0 | 1 | 4 | 0 | 2.80 |
| Kodiak Sciences | 1 | 2 | 1 | 0 | 2.00 |
Metagenomi currently has a consensus target price of $14.40, suggesting a potential upside of 778.05%. Kodiak Sciences has a consensus target price of $8.00, suggesting a potential upside of 143.90%. Given Metagenomi’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Kodiak Sciences.
Profitability
This table compares Metagenomi and Kodiak Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Metagenomi | -134.27% | -43.23% | -18.86% |
| Kodiak Sciences | N/A | -84.52% | -45.40% |
Summary
Metagenomi beats Kodiak Sciences on 9 of the 12 factors compared between the two stocks.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
